ABSTRACT
Antibody replacement using human gammaglobulin is essential in the treatment of patients with profound deficiency of immunoglobulin (1). Deficiency of IgG subclasses has been associated with a number of immunodeficiency syndromes; the discussion below addresses IgG subclass deficiency as a distinct entity. Assessing efficacy of intravenous immunoglobulin (IVIG) (or any form of therapy) for patients who have selective deficiency of IgG subclasses will be difficult until confusion about this syndrome has been resolved.
